Simonsen A H, McGuire J, Podust V N, Hagnelius N-O, Nilsson T K, Kapaki E, Vassilopoulos D, Waldemar G
Biomarker Discovery Center Facility, Ciphergen Biosystems Inc., Copenhagen, Denmark.
Dement Geriatr Cogn Disord. 2007;24(6):434-40. doi: 10.1159/000110576. Epub 2007 Oct 30.
An early and accurate diagnosis of Alzheimer's disease (AD) is important in order to initiate symptomatic treatment with currently approved drugs and will be of even greater importance with the advent of disease-modifying compounds.
Protein profiles of human cerebrospinal fluid samples from patients with AD (n = 85), frontotemporal dementia (n = 20), and healthy controls (n = 32) were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to verify previously discovered biomarkers.
We verified 15 protein biomarkers that were able to differentiate between AD and controls, and 7 of these 15 markers also differentiated AD from FTD.
A panel of cerebrospinal fluid protein markers was verified by a proteomics technology which may potentially improve the accuracy of the AD diagnosis.
为了使用当前获批药物启动对症治疗，阿尔茨海默病（AD）的早期准确诊断很重要，并且随着疾病修饰化合物的出现，其重要性将更加凸显。
通过表面增强激光解吸/电离飞行时间质谱分析来自AD患者（n = 85）、额颞叶痴呆患者（n = 20）和健康对照者（n = 32）的人脑脊液样本的蛋白质谱，以验证先前发现的生物标志物。
我们验证了15种能够区分AD与对照的蛋白质生物标志物，这15种标志物中的7种也能区分AD与额颞叶痴呆（FTD）。
通过蛋白质组学技术验证了一组脑脊液蛋白质标志物，这可能会提高AD诊断的准确性。
